On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema. Read more.
On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema. Read more.